DIQTA 1.0: Drug-Induced QT Prolongation Atlas

VASOPRESSIN

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Most-DIQT concern

Severity Score:4.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

OVERDOSAGE
Overdosage with Vasostrict® can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.
Direct effects will resolve within minutes of withdrawal of treatment.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24092

Other ADRs

38381587

Odds Ratio = N/A

Drug Property Information

ATC Code(s):

H01BA01 - vasopressin

H01BA0 -
H01BA - Vasopressin and analogues
H01B - POSTERIOR PITUITARY LOBE HORMONES
H01 - PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H - "SYSTEMIC HORMONAL PREPARATIONS, EXCL. "

Active Ingredient:VASOPRESSIN, UNSPECIFIED

Active Ingredient UNII:Y87Y826H08

Drugbank ID:DB00067

PubChem Compound:N/ADIR Classification

CTD ID:D014667

PharmGKB:PA451858

CAS Number:11000-17-2

Dosage Form(s):injection

Route(s) Of Administrator:intravenous

Daily Dose:

40.0 mg/day H01BA01

Chemical Structure:

SMILE Code:
NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O

Reference

1: Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.

[Woosley R David,Romero Klaus,Heise Craig W,Gallo Tyler,Tate Jared,Woosley Raymond L]
Drug Saf,2019 Jul;42(7):907-913. PMID: 30888625

2: Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers.

[Lasseter Kenneth C,Dilzer Stacy C,Smith Neila]
Adv Ther,Mar-Apr 2007;24(2):310-8. PMID: 17565921

3: Prediction of torsade-causing potential of drugs by support vector machine approach.

[Yap C W,Cai C Z,Xue Y,Chen Y Z]
Toxicol Sci,2004 May;79(1):170-7. PMID: 14976348

4: Drug interactions with cisapride: clinical implications.

[Michalets E L,Williams C R]
Clin Pharmacokinet,2000 Jul;39(1):49-75. PMID: 10926350

5: [Clinico-pharmacological case (2). Bradycardia and ventricular tachycardia of the torsades de pointes type as a side effect of vasopressin: 3 case reports].

[Kupferschmidt H,Meier C H,Sulzer M,Meier P J,Bühler H]
Praxis (Bern 1994),1996 Mar 12;85(11):340-3. PMID: 8643894

6: Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance.

[Faigel D O,Metz D C,Kochman M L]
Am J Gastroenterol,1995 May;90(5):822-4. PMID: 7733096

7: Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin.

[Stein L B,Dabezies M A,Silverman M,Brozena S C]
J Clin Gastroenterol,1992 Sep;15(2):171-4. PMID: 1401838

8: Torsade de pointes in a patient receiving intravenous vasopressin.

[Mauro V F,Bingle J F,Ginn S M,Jafri F M]
Crit Care Med,1988 Feb;16(2):200-1. PMID: 3257726

9: Ventricular arrhythmia induced by vasopressin: torsade de pointes related to vasopressin-induced bradycardia.

[Eden E,Teirstein A,Wiener I]
Mt Sinai J Med,Jan-Feb 1983;50(1):49-51. PMID: 6601760

Search for drugs: